Every lot is tried & tested in a relevant biological assay.
- Horne, A.L. et al. (1992) Br. J. Pharmacol. 107, 732.
- Alomone Labs (+)-Bicuculline inhibits GABA(A) α2/β1/γ2 currents activated by γ-Aminobutyric acid in heterologously expressing Xenopus oocytes.Time course of γ-Aminobutyric acid (#G-110) (100 µM) activated GABA(A) α2/β1/γ2 currents and their inhibition by 20 µM (+)-Bicuculline (#B-135), which was perfused for 100 seconds as indicated by the horizontal bar. Holding membrane potential was -60 mV and γ-aminobutyric acid was applied every 100 seconds.
γ-Aminobutyric acid (GABA) is an amino acid derivate, synthesized from glutamate by the pyridoxal-L-phosphate (PLP)-dependent enzyme, glutamate decarboxylase (GAD)1. GABA provides the primary inhibitory signaling in the adult mammalian brain (CNS), and, to some degree of controversy, exerts a depolarizing response in the developing brain2.
GABA is an agonist of two main receptor classes in the CNS: GABAA, an ionic ligand-gated channel, and GABAB, a metabotrophic, G-protein coupled receptor. GABAA is assembled by 5 out of 16 possible subunits with α, β and either a γ or a δ (2:2:1 stoichiometry) being the most common. With an EC50 between 3 to 12 μM it interacts with GABA to allow either an influx or an efflux of Cl- ions into and out of the cell, respectively3.
Bicuculline (BIC) is a competitive allosteric inhibitor of GABAA-induced currents with an IC50 of 1-3 μM4. BIC has been employed to model epileptic seizures in hippocampal slices5, to induce schizophrenia-like symptoms in the pre-frontal cortex6, and is an essential research tool in the study of various psychomotor and behavioral defects4-6.